Peculiarities of morphological changes in estimation of efficacyof neoadjuvant targeted therapy in patients, suffering localizedrenal–cell cancer
Objective. To determine the peculiarities ofmorphological changes under the influence of neoadjuvant targeted therapy (TTH) in patients, suffering localized renal-cell cancer (RCC).
Маterials and methods. The investigation was performed in 58 patients, suffering localized RCC, in whom two blocks of neoadjuvant TTH were conducted for determination of objective answer on treatment accomplished with further operative intervention and pathomorphological investigation.
Results. Median index of tumoral regression (М ± SD) after conduction of ТТH have constituted (20.5 ± 14.3)% (95% confidence interval - CІ 16 - 24.3). Estimation of tumoral regression in accordance to RECIST 1.1 have witnessed, that stabilization was registered in 44 (75.9%) patients, and partial regression - in 14 (24.1%). Сomplete regression or progression of the process was not observed in any patient. Median index of regression while presence of the Degree II process, in accordance to Furman method, have constituted (22.6 ± 14.4)% (95% CІ 18.3 - 26.9); Degree III in accordance to Furman method - (17.1 ± 11.7) (95% CІ 7.3 - 26.9); and the Degree IV in accordance to Furman method - (3.8 ± 2.9)% (95% CІ -1 - 8,5); estimation in accordance to ANOVA method: η2=0.13; power=0.72; p < 0.05. Median index of tumoral necrosis under the impact of ТТH is trustworthily higher in patients with partial regression. Correlation dependence of the vascular changes severity and viable part of tumoral tissue from degree of the RCC regression was not revealed.
Conclusion. Tumoral regression by (20.5 ± 14.3)% at average have occurred under the impact of neoadjuvant TTH in patients, suffering localized RCC. Low index of the RCC regression in patients, having histopathological nuclear Degree IV in accordance to Furman method have constituted (3.8 ± 2.9)%, what witnessed low TTH efficacy (estimation in accordance to ANOVA method: η2 = 0.13; power = 0.72; p < 0.05), and may be applied as a prognostic marker of answer.
2. Lattouf JB, Trinh QD, Saad F. The contemporary role of surgery in kidney cancer. Curr Oncol. 2009 May;16 Suppl 1:S8-S15. PMID: 19478900.
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 1;27(22):3584-90. https://doi.org/10.1200/JCO.2008.20.1293.
4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47 https://doi.org/10.1016/j.ejca.2008.10.026.
5. Stakhovskiy EO, Voylenko OA, Vitruk YV, Stakhovskiy OE. Application of nephrometry for choice of the treatment tactics in patients, suffering nephrocellular cancer Klin Khir. 2015 Mar;(3):55-60. PMID:26072547. [In Ukrainian].
6. Halakhyn K.A., Kuryk E.H. Lechebniy patomorfoz zlokachestvennikh opukholey pyshchevarytelnoho trakta. Kiev: Knyha-plyus; 2000. 176 с. [In Russian].
7. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016 Jul;70(1):93-105. https://doi.org/10.1016/j.eururo.2016.02.029.
8. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009 Mar 28;373(9669):1119-32. https://doi.org/10.1016/S0140-6736(09)60229-4.
9. Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, et al. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urol Oncol. 2018 Jan;36(1):31-37. https://doi.org/10.1016/j.urolonc.2017.07.015.
10.Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron- sparing surgery. BJU Int 2010 Nov;106(9):1270-6. https://doi.org/10.1111/j.1464-410X.2010.09357.
11. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. https://doi.org/10.1056/NEJMoa1712126.
12. Sim SH, Messenger MP, Gregory WM, Wind TC, Vasudev NS, Cartledge J, et al. Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer. 2012 Sep 25;107(7):1131-7. https://doi.org/10.1038/bjc.2012.360.
13. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009 Jun 1;27(16):2645-52 https://doi.org/10.1200/JCO.2008.19.1106.
14. Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014 Aug;25(8):1603-8. https://doi.org/10.1093/annonc/mdu184.
Copyright (c) 2019 Liga-Inform
This work is licensed under a Creative Commons Attribution 4.0 International License.